# CKD Venture Capital Corporation

> CKD Venture Capital Corporation is a VC fund in Seoul backing Biotechnology and Health Care. See 29 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 29
- Last investment: Mar 2026
- Lead investor: 7%
- Last updated: Aug 2026
- Website: http://www.ckdvc.co.kr

CKD Venture Capital Corporation is a Seoul, Korea-based venture capital firm. Founded in 1997, CKD Venture Capital Corporation considers seed, early stage, late stage and mezzanine investments.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.7M–$3M |
| Series A | $3.3M–$10M |
| Series B | $497k–$18M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 34% |
| Health Care | 7 | 24% |
| Therapeutics | 7 | 24% |
| Pharmaceutical | 4 | 14% |
| Information Technology | 4 | 14% |

44 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 13 | 45% |
| Series B | 7 | 24% |
| Seed | 4 | 14% |
| Series C | 2 | 7% |
| Series D | 1 | 3% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cenyx Biotech | Cenyx Biotech develops diagnostic and therapeutic nano-compounds formed based on nanozymes and nanoparticles. | $8.2M | Series B | Mar 31, 2026 |  |
| 1st Biotherapeutics | 1STBIO is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in-class therapeutic candidates with highly likelihood of clinical success. 1STBIO currently has 24 employees with expertise in biochemistry, medicinal chemistry,pharmacology, and business development. We are working as a core expertise team of drug discovery/development and are rigorously connected to R&D networking of academia, hospitals, industry, CRO’s and investors in Korea, China and US. Our ultimate goal is to use our experience and knowledge to discover and develop effective molecular therapeutics for patients. | $21.9M | Series D | Jan 26, 2026 |  |
| Portrai | Portrai is a biotechnology research company utilizing AI in spatial transcriptomics to improve biopsy quality. The company specializes in developing highly accurate artificial intelligence technology to analyze spatial transcriptomics results. This enables doctors to efficiently examine a patient's illness by analyzing tissue samples withprecision. | $9.9M | Series B | Dec 02, 2025 |  |
| Qunova Computing, Inc. | Quantum computing based computing innovations for new materials and drug discovery, and advanced technology solution consulting services. | $10M | Series A | Aug 18, 2025 |  |
| ROBOS | Robos is a hybrid robot system built by evaluating biological object vision data using Lidar Vision and Open CV-based Object Detection. By combining self-developed biomaterial machine vision technology and robot technology, it intends to expand into a company that delivers core services to diverse industrial sites such as manufacturing, food, andmedical. | $18.2M | Series B | Jun 18, 2025 |  |
| Pin Therapeutics | Pin Therapeutics is founded in Feb 2017, fast growing stage with member composition of 25% in USA and 75% in Korea. Drug discovery leaderships are from global pharma and biotech companies along with talented scientists both in Korea and USA.* Active Focus - PinE3: E3 ligase screening cascade for identifying novel warheads - PinGLUE: Assaycascade for molecular glue degrader screening* Programs - Selective Molecular Glue Degrader (CK1α) - Molecular Glue Degrader Programs (5-6 Undisclosed) - PROTAC Program (1 Undisclosed) | $13.6M | Series C | Dec 27, 2024 |  |
| ROBOS | Robos is a hybrid robot system built by evaluating biological object vision data using Lidar Vision and Open CV-based Object Detection. By combining self-developed biomaterial machine vision technology and robot technology, it intends to expand into a company that delivers core services to diverse industrial sites such as manufacturing, food, andmedical. | $5.2M | Series A | Feb 13, 2024 |  |
| Medinno | Medinno develops cell therapeutics for brain diseases. The company's therapy uses technology to treat a wide range of diseases, including hypoxic-ischemic encephalopathy, neonatal refractory brain diseases, and severe intraventricular hemorrhages.. | $8.2M | Series C | Oct 16, 2023 |  |
| Cellemedy | ​Cellemedy is a biotechnology company committed to developing next-generation therapeutic proteins aimed at replacing conventional antibody treatments. Their proprietary platform offers enhanced antigen-binding capabilities and broader applicability compared to traditional antibodies. Its mission is to advance human health by creating innovativebiopharmaceuticals that improve treatment outcomes across various medical conditions. ​ | $7.4M | Series A | Oct 04, 2023 |  |
| Zymedi | Zymedi is a pharmaceutical company that develops drugs for life-threatening diseases. | $12.1M | Series A | May 30, 2023 |  |

10 of 29 investments shown.

## Co-investors
- [KT Investment](https://shizune.co/investors/profile/kt-investment-inc) — VC Fund, 4 deals together
- [Smilegate Investment](https://shizune.co/investors/profile/smilegate-investment) — VC Fund, 4 deals together
- [Daekyo Investment](https://shizune.co/investors/profile/daekyo-investment-0481) — VC Fund, 3 deals together
- [Dt& Investment](https://shizune.co/investors/profile/dt-investment) — VC Fund, 3 deals together
- [FuturePlay](https://shizune.co/investors/profile/futureplay-co) — VC Fund, 3 deals together
- [Hyundai Technology Investment](https://shizune.co/investors/profile/hyundai-technology-investment) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [Agriculture (agtech) Investors in South Korea](https://shizune.co/investors/agriculture-agtech-investors-south-korea)
- [Agriculture (agtech) VC Funds in South Korea](https://shizune.co/investors/agriculture-agtech-vc-funds-south-korea)
- [Enterprise Investors in South Korea](https://shizune.co/investors/enterprise-investors-south-korea)
- [Proptech Investors in South Korea](https://shizune.co/investors/proptech-investors-south-korea)
- [Enterprise VC Funds in South Korea](https://shizune.co/investors/enterprise-vc-funds-south-korea)
- [Agriculture (agtech) Investors in South Korea](https://shizune.co/investors/agriculture-agtech-investors-south-korea)

## FAQ

### What does CKD Venture Capital Corporation invest in?

CKD Venture Capital Corporation invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 29 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is CKD Venture Capital Corporation's check size?

CKD Venture Capital Corporation typically joins rounds of $1.7M–$3M at Seed, $3.3M–$10M at Series A and $497k–$18M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds CKD Venture Capital Corporation participates in.

### When did CKD Venture Capital Corporation last invest?

The most recent investment recorded for CKD Venture Capital Corporation closed in Mar 2026. Shizune tracks 29 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co